INmune Bio Inc

INmune Bio Inc. a clinical-stage immunology company focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies solid tumors and chronic inflammation. The company's development programs include INKmune which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4 a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor Inc.; Immune Ventures LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton Florida.